Tranexamic Acid vs Vasopressin in Placenta Previa Trial

What Was Tested

This registered phase 3 trial tested Vasopressin.

It had two arms (groups): Tranexamic Acid (TXA) Group (experimental) and Vasopressin Group (experimental).

Arm 1: Tranexamic Acid Group (TXA Group) Number of participants: 29 Description: Patients with placenta previa undergoing elective cesarean section receiving tranexamic acid prophylactically before surgery.

Arm 2: Vasopressin Group Number of participants: 29 Description: Patients with placenta previa undergoing elective cesarean section receiving vasopressin prophylactically.

The registry classes the interventions as drug.

More on the Plan

A total sample size of 58 patients will be enrolled through non-probability purposive sampling.

Women aged 18-45 years with singleton pregnancy and placenta previa scheduled for elective cesarean section will be included.

Patients undergoing emergency cesarean section, having coagulation disorders, chronic liver/kidney disease, gestational diabetes, hypertensive disorders of pregnancy, history of postpartum hemorrhage, or using anticoagulant/antiplatelet drugs will be excluded.

After informed consent, baseline characteristics including age, gravida, para, abortion history, grade of placenta previa, and pre-operative hemoglobin will be recorded.

Who Took Part

The registry lists 58 planned participants were the target.

It was open to women only aged from 18 years up to 45 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

The Vasopressin group and the comparison group ran side by side rather than switching.

Being open-label, the Vasopressin study did not mask who received what.

It started in 2026-03-01 with completion listed for 2026-08-31.

It ran at 1 site in Pakistan.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Intraoperative Blood Loss.

It also tracked 2 secondary outcomes, for example Need for Blood Transfusion.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Vasopressin in 58 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Vasopressin compound page, all human trials.